Literature DB >> 14716698

Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).

Frans R Verhey1, Peter Houx, Natascha Van Lang, Felicia Huppert, Gabriella Stoppe, Jos Saerens, Peter Böhm, Luc De Vreese, Arto Nordlund, Peter P DeDeyn, Mirco Neri, Jordi Peña-Casanova, Anders Wallin, Eduard Bollen, Huub Middelkoop, Marie-Christine Nargeot, Michèle Puel, Ulrich M Fleischmann, Jellemer Jolles.   

Abstract

BACKGROUND: The Alzheimer's Disease Assessment Scale (ADAS) is often used in international multicenter trials. Use across countries presupposes correct translation and adaptation of the scale, and maintenance of its psychometric properties.
OBJECTIVES: To compare the various translations of the ADAS used in Western Europe, to design internationally harmonized translations and to validate these.
SETTING: International cooperative study in eight European countries.
METHODS: An inventory was made of existing versions of the ADAS-Cog used in eight European countries, and adaptations were made. The concurrent validity of the harmonized versions of the ADAS was tested in 283 patients with probable or possible Alzheimer's disease. The Nurses Observation Scale for Geriatrics (NOSGER), CAMCOG-R and MMSE was used to assess concordance between cognitive and behavioral measures.
RESULTS: Differences between the versions mainly involved object naming, items for verbal memory, such as the number of trials allowed, the imagery value of the words selected as targets or distractors, and the number of parallel versions. These differences were eliminated by adapting and harmonizing the various versions of the ADAS-Cog. Thereafter, only small differences between the different countries were found, and patterns of correlation between ADAS-Cog, and the NOSGER, CAMCOG-R and MMSE were consistent.
CONCLUSIONS: The study underlines the need to use harmonized versions of instruments for rating dementia in multinational studies. The findings indicate that the harmonization of the ADAS-Cog was successful. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14716698     DOI: 10.1002/gps.1035

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  11 in total

1.  Administration and scoring variance on the ADAS-Cog.

Authors:  Donald J Connor; Marwan N Sabbagh
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

2.  A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial.

Authors:  Kathleen M Hayden; Oksana A Makeeva; L Kristin Newby; Brenda L Plassman; Valentina V Markova; Ashley Dunham; Heather R Romero; Zarui A Melikyan; Cassandra M Germain; Kathleen A Welsh-Bohmer; Allen D Roses
Journal:  Alzheimers Dement       Date:  2014-07-22       Impact factor: 21.566

3.  TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.

Authors:  Edward Tobinick; Hyman Gross; Alan Weinberger; Hart Cohen
Journal:  MedGenMed       Date:  2006-04-26

4.  Study design considerations: conducting global clinical trials in early Alzheimer's disease.

Authors:  R J Schindler
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

5.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Authors:  Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan
Journal:  Ann Neurol       Date:  2016-11-07       Impact factor: 10.422

Review 6.  Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.

Authors:  Edward Tobinick
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

7.  Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Authors:  Joshua D Grill; Rema Raman; Karin Ernstrom; Paul Aisen; Sherie A Dowsett; Yun-Fei Chen; Hong Liu-Seifert; Ann Marie Hake; David S Miller; Rachelle S Doody; David B Henley; Jeffrey L Cummings
Journal:  Alzheimers Res Ther       Date:  2015-06-25       Impact factor: 6.982

8.  Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment.

Authors:  J A van Deursen; E F P M Vuurman; F R J Verhey; V H J M van Kranen-Mastenbroek; W J Riedel
Journal:  J Neural Transm (Vienna)       Date:  2008-07-08       Impact factor: 3.575

9.  Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.

Authors:  Edward L Tobinick; Hyman Gross
Journal:  BMC Neurol       Date:  2008-07-21       Impact factor: 2.474

10.  A three-year follow-up on the efficacy of psychosocial interventions for patients with mild dementia and their caregivers: the multicentre, rater-blinded, randomised Danish Alzheimer Intervention Study (DAISY).

Authors:  Kieu T T Phung; F B Waldorff; D V Buss; A Eckermann; N Keiding; S Rishøj; V Siersma; J Sørensen; R Søgaard; L V Sørensen; A Vogel; G Waldemar
Journal:  BMJ Open       Date:  2013-11-21       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.